

Ref: SPL/CORP-SEC/2024-25/BSE/270

Dated:20.11.2024

To,

Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: : Corrigendum to the Unaudited Financial Results of the Company for the period ended on September 30, 2024.

Ref: Regulations 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations. 2015.

Dear Sir/Madam,

With reference to our Board meeting announcement dated 14th November, 2024 with regards to Un-audited Financial Results of the company for the quarter and half year ended on September 30, 2024, we would like to intimate to the exchange regarding inadvertent minor clerical error related to disclosure in the 'Statement of Unaudited Consolidated Financial Results below mentioned

1. Earning Per Share- EPS for quarter ended on 30th September, 2024, which have been disclosed as 1.95 under Basic and Diluted instead of 0.52 under basic and Diluted.
2. Earning Per Share-EPS for half year ended on 30th September 2024 which have been disclosed as 1.46 under Basic and Diluted instead of 0.69 under basic and Diluted.

The corrected EPS table should be read as under:

							(Rs in Lakhs)
		Quarter Ended			Half Year ended		
	Particulars	Qtr Ending September 2024	Qtr Ending June 2024	Qtr Ending September 2023	Half Year ended 30-09-2024	Corresponding half year Ended 30-09-2023	Year Ended March 2024
XVI	Earnings per equity share (for continuing operation):						
	(1) Basic	0.52	0.17	0.57	0.69	0.68	1.51
	(2) Diluted	0.52	0.17	0.57	0.69	0.68	1.51

In these regards we enclose herewith revised 'Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year Ended on 30th September, 2024'. We would further like to inform that there are no changes in the current Quarter and Half Year Ended on 30th September, 2024' financial result and the same is to be taken



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

on record.

There are no other changes except above mentioned and corrected in the Un-audited Financial Results of the company for the quarter and half year ended on September 30, 2024 and as approved by the board of directors in its meeting held on November 14, 2024.

Kindly take this information on your records.

FOR SANDU PHARMACEUTICALS LTD.

Pratika Mhambray
Company Secretary
ACS :36512



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

CONSOLIDATED STATEMENT OF UNAUDITED RESULTS FOR THE PERIOD ENDED 30/09/24						
Particulars	Quarter Ended			Half Year ended		
	Qtr Ending September 2024	Qtr Ending June 2024	Qtr Ending September 2023	Half Year ended 30-09-2024	Corresponding half year Ended 30-09-2023	Year Ended March 2024
	(Un audited)	(Un audited)	(Audited)	(Un Audited)	(Un Audited)	(Audited)
						(Rs in Lakhs)
Revenue From Operations	1770.49	1,704.54	1,660.71	3475.03	3,426.42	6,728.07
Other Income	2.87	4.49	8.70	7.36	8.80	42.36
Total Income (I+II)	1773.36	1,709.03	1,669.41	3482.39	3,435.22	6,770.43
EXPENSES						
Cost of materials consumed	243.86	227.41	261.62	471.27	459.37	985.26
Purchases of Stock-in-Trade	540.64	394.11	579.70	934.75	907.40	2,108.28
Changes in inventories of finished goods,	31.58	308.49	-11.49	340.07	407.64	163.48
Stock-in -Trade and work-in-progress						
Employee benefits expense	260.76	232.82	254.77	493.58	506.95	1,007.32
Finance costs	2.83	2.12	1.48	4.95	3.82	6.31
Depreciation and amortization expense	17.41	15.88	13.27	33.29	25.51	58.33
Other expenses	602.59	501.13	493.62	1103.72	1,026.98	2,234.17
Total expenses (IV)	1699.67	1,681.96	1,592.97	3381.63	3,337.66	6,563.14
Profit/(loss) before exceptional items and tax (I- IV)	73.70	27.07	76.45	100.77	97.56	207.29
Exceptional Items						-
Profit/(loss) before tax (V-VI)	73.70	27.07	76.45	100.77	97.56	207.29
Tax expense:						
(1) Current tax	20.77	7.55	21.19	28.52	26.93	58.71
(2) Deferred tax	3.40	2.85	0.20	6.26	4.60	2.46
Short / (Excess) Tax Provision		-				
Profit (Loss) for the period from continuing operations (VII-VIII)	49.52	16.66	55.06	65.98	66.03	146.12
Profit/(loss) for the period (IX+XII)	49.52	16.66	55.06	65.98	66.03	146.12
Other Comprehensive Income						
A (i) Items that will not be reclassified to profit or loss						
a. Remeasurement gains/(losses) on post employment defined benefit plans						(11.96)
b. Fair value changes of investments	19.94	21.11	19.82	41.06	37.93	78.90
(ii) Income tax relating to items that will not be reclassified to profit or loss	-2.22	(2.35)	(0.19)	-4.57	(2.20)	(5.45)
B (i) Items that will be reclassified to profit or loss						
(ii) Income tax relating to items that will be reclassified to profit or loss		-	-			-
Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	67.24	35.42	74.69	102.48	101.76	207.61
Paid Up Equity Capital (Face Value of Rs 10/- Per share)	966.10	966.10	966.10	966.10	966.10	966.10
Earnings per equity share (for continuing operation):						
(1) Basic	0.52	0.17	0.57	0.69	0.68	1.51
(2) Diluted	0.52	0.17	0.57	0.69	0.68	1.51

Place :- Mumbai
Date- 14/11/2024

For Sandu Pharmaceuticals Ltd

Umesh Sandu
Managing Director
DIN :- 01132141